Curebase Inks $15M Series A For New Approach To Clinical Trials
Originally published at Crunchbase.com
Curebase raised $15 million in Series A funding toward the development of its decentralized clinical trial software platform that enables research to be conducted with any patient in their home and with their own doctor.
GGV Capital led the round with participation from institutional investors, including Xfund and Bold Capital. The new capital brings Curebase’s total raise to $18.9 million, according to Curebase CEO Tom Lemberg.
The global pandemic halted many in-person clinical trials that involve patients traveling to academic institutions and medical centers, leading many to adopt decentralized clinical trials following U.S. Food and Drug Administration guidance.
Founded in 2017, the San Francisco-based company’s platform is going after the $50 billion clinical trial industry with study designs that enable the trials to happen around the patient’s lifestyle, which makes them faster, more cost-effective and can provide a more diverse mix of patients, Lemberg told Crunchbase News.
Continue Reading at Crunchbase